Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.

Bruce A. C. Cree,Jeffrey L. Bennett,Ho Jin Kim,Brian G Weinshenker,Sean J Pittock,Dean M. Wingerchuk,Kazuo Fujihara,Friedemann Paul,Gary Cutter,Romain Marignier,Ari J. Green,Orhan Aktas,Hans-Peter Hartung,Ian M. Williams,Jorn Drappa,Dewei She,Daniel Cimbora,William Rees,John N. Ratchford,Eliezer Katz

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.

2021

Background:In the N-MOmentum trial, the risk of an adjudicated neuromyelitis optica spectrum disorder (NMOSD) attack was significantly reduced with inebilizumab compared with placebo.Objective:To d...

Keywords:

Neuromyelitis optica
patient demographics
Clinical endpoint
Clinical trial
Multiple sclerosis
Spectrum disorder
sensitivity analyses
Medicine
Pediatrics
Inebilizumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations